Significance of MAIT Cells in Inflammatory Bowel Disease

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05598346
Collaborator
(none)
70
13

Study Details

Study Description

Brief Summary

To examine the level and function of MAIT cells in IBD patients, and to compare it with disease activity.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory diseases of unknown origin. IBD has become a global disease with increasing incidence in newly industrialized and westernized countries. Genetic and environmental factors with inadequate host immune response to gut flora appear to play important roles in the pathogenesis of IBD. Adaptive immune response has been classically considered to play a major role in IBD pathogenesis .

    Infiltrating lymphocytes including T helper (Th) 1 cells and Th17 cells can lead to the development of intestinal lesions . However, recent evidences suggest that innate immune response is equally important in inducing gut inflammation . Altered epithelial barrier function and aberrant innate immune responses contribute to intestinal inflammation in IBD patients.

    Mucosal-associated invariant T (MAIT) cells are innate lymphocytes that express a conserved invariant Tcell receptor (TCR) Vα7.2-Jα33 chain paired with a limited set of Vβ chains. Using distinct pairs of TCR chains, MAIT cells can recognize bacteria-derived riboflavin (vitamin B2) metabolites presented by MHC(major histocompatibility complex) class 1b-like related protein (MR1).

    Upon MR1-dependent recognition of antigens, MAIT cells are activated to rapidly release Th1/Th17 proinflammatory cytokines (i.e., interferon [IFN]-γ, tumor necrosis factor [TNF]-α, and interleukin [IL]-17 and cytotoxic molecules (i.e.,granzyme and perforin) to kill infected host cells.

    MAIT cells are abundant in peripheral blood where they where they express gut-homing chemokine receptors such as CCR6(chemokine receptor type 6) and CCR9(chemokine receptor type9). They are also abundant in intestinal mucosa where they likely confront normal flora or pathogenic bacteria producing bacterial ligands.

    Given tissue- homing properties and rapid production of proinflammatory cytokines, MAIT cells may play an important role in infectious diseases and autoimmune disorders.

    Results from experiment with transfer of MAIT cells to TNBS(trinitrobenzene sulfonic acid)-induced IBD murine models suggest that MAIT cells might play a protective role in TNBS-induced intestinal inflammation . In addition, previous studies have reported MAIT cell dysfunction in IBD patients. However, the role of MAIT cells in IBD patients remains unclear.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    70 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Retrospective
    Official Title:
    Significance and Biological Importance of Mucosal Associated Invariant T Cells in Inflammatory Bowel Disease Patients
    Anticipated Study Start Date :
    Mar 1, 2023
    Anticipated Primary Completion Date :
    Mar 1, 2024
    Anticipated Study Completion Date :
    Apr 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Detection of MAIT cells level in IBD,Compare its level with disease activity [Baseline]

      Monoclonal Antibodies by flow cytometry used for detection of MAIT cells in IBD patients

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    15 Years to 50 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Patients with active IBD according to clinical scores with the following:
    1. Recently discovered.

    2. Average age (15-50).

    Exclusion Criteria:
    • Patient with history of any of the following ;
    1. History of respiratory disorders such as chronic obstructive diseases, pulmonary disease or pulmonary embolism.

    2. Other Autoimmune diseases, infectious diseases.

    3. Recent surgery, malignancies, left ventricular dysfunction, use of immunosuppressive drugs.

    4. Chronic liver, renal, and endocrine diseases.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AL shimaa Mohamed salahidden, principle investigator, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05598346
    Other Study ID Numbers:
    • MAIT cells in In IBD
    First Posted:
    Oct 28, 2022
    Last Update Posted:
    Nov 14, 2022
    Last Verified:
    Nov 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by AL shimaa Mohamed salahidden, principle investigator, Assiut University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 14, 2022